These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29513767)

  • 21. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.
    Beer L; Mandorfer M; Bastati N; Poetter-Lang S; Tamandl D; Stoyanova DP; Elmer MC; Semmler G; Simbrunner B; Hodge JC; Sirlin CB; Reiberger T; Ba-Ssalamah A
    Eur Radiol; 2019 Dec; 29(12):6600-6610. PubMed ID: 31001679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis.
    Nilsson H; Blomqvist L; Douglas L; Nordell A; Jacobsson H; Hagen K; Bergquist A; Jonas E
    J Magn Reson Imaging; 2014 Apr; 39(4):879-86. PubMed ID: 24123427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of hepatic fractional extracellular space using gadolinium enhanced MRI with liver stiffness using magnetic resonance elastography.
    Wells ML; Moynagh MR; Carter RE; Childs RA; Leitch CE; Fletcher JG; Yeh BM; Venkatesh SK
    Abdom Radiol (NY); 2017 Jan; 42(1):191-198. PubMed ID: 27511365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging.
    Li Z; Sun J; Chen L; Huang N; Hu P; Hu X; Han G; Zhou Y; Bai W; Niu T; Yang X
    J Magn Reson Imaging; 2016 Jul; 44(1):98-104. PubMed ID: 26707910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression.
    Elkilany A; Geisel D; Müller T; Fischer A; Denecke T
    Abdom Radiol (NY); 2021 Mar; 46(3):979-991. PubMed ID: 32918576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC).
    Hinrichs H; Hinrichs JB; Gutberlet M; Lenzen H; Raatschen HJ; Wacker F; Ringe KI
    Eur Radiol; 2016 Apr; 26(4):1116-24. PubMed ID: 26205638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of high-stage liver fibrosis using ADC value on diffusion-weighted imaging and quantitative enhancement ratio at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI at 1.5 T.
    Harada TL; Saito K; Araki Y; Matsubayashi J; Nagao T; Sugimoto K; Tokuuye K
    Acta Radiol; 2018 May; 59(5):509-516. PubMed ID: 28853292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.
    Jhaveri KS; Hosseini-Nik H; Sadoughi N; Janssen H; Feld JJ; Fischer S; Menezes R; Cheung AC
    Eur Radiol; 2019 Feb; 29(2):1039-1047. PubMed ID: 30051141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
    Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR imaging of primary sclerosing cholangitis: additional value of diffusion-weighted imaging and ADC measurement.
    Kovač JD; Ješić R; Stanisavljević D; Kovač B; Maksimovic R
    Acta Radiol; 2013 Apr; 54(3):242-8. PubMed ID: 23386736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-Tesla magnetic resonance elastography for hepatic fibrosis: comparison with diffusion-weighted imaging and gadoxetic acid-enhanced magnetic resonance imaging.
    Park HS; Kim YJ; Yu MH; Choe WH; Jung SI; Jeon HJ
    World J Gastroenterol; 2014 Dec; 20(46):17558-67. PubMed ID: 25516671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.
    Ringe KI; Hinrichs J; Merkle EM; Weismüller TJ; Wacker F; Meyer BC
    J Magn Reson Imaging; 2014 Jul; 40(1):106-12. PubMed ID: 24923477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.
    Ehlken H; Wroblewski R; Corpechot C; Arrivé L; Rieger T; Hartl J; Lezius S; Hübener P; Schulze K; Zenouzi R; Sebode M; Peiseler M; Denzer UW; Quaas A; Weiler-Normann C; Lohse AW; Chazouilleres O; Schramm C
    PLoS One; 2016; 11(10):e0164224. PubMed ID: 27723798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
    Jin YJ; Lee SH; Cho SG; Kim JH; Lee JW; Lee KY; Shin WY
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1349-56. PubMed ID: 26916616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index.
    Motosugi U; Ichikawa T; Oguri M; Sano K; Sou H; Muhi A; Matsuda M; Fujii H; Enomoto N; Araki T
    Magn Reson Imaging; 2011 Oct; 29(8):1047-52. PubMed ID: 21775085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver fibrosis and Gd-EOB-DTPA-enhanced MRI: A histopathologic correlation.
    Verloh N; Utpatel K; Haimerl M; Zeman F; Fellner C; Fichtner-Feigl S; Teufel A; Stroszczynski C; Evert M; Wiggermann P
    Sci Rep; 2015 Oct; 5():15408. PubMed ID: 26478097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
    Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
    Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between severity of liver dysfunction and the relative ratio of liver to aortic enhancement (RE) on MRI using hepatocyte-specific contrast.
    Kim YC; Kim MJ; Park YN; Kim KS; Ahn SH; Jung SE; Kim JK
    J Magn Reson Imaging; 2014 Jan; 39(1):24-30. PubMed ID: 23553935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis.
    Li XM; Chen Z; Xiao EH; Shang QL; Ma C
    World J Gastroenterol; 2017 May; 23(17):3133-3141. PubMed ID: 28533670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver dynamic contrast-enhanced MRI for staging liver fibrosis in a piglet model.
    Zhou L; Chen TW; Zhang XM; Yang Z; Tang HJ; Deng D; Zeng NL; Wang LY; Chen XL; Li H; Li CP; Li L; Xie XY; Hu J
    J Magn Reson Imaging; 2014 Apr; 39(4):872-8. PubMed ID: 24123400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.